KR20230173108A - 암 치료에서 1차 요법으로 sEphB4-HSA 융합 단백질의 용도 - Google Patents

암 치료에서 1차 요법으로 sEphB4-HSA 융합 단백질의 용도 Download PDF

Info

Publication number
KR20230173108A
KR20230173108A KR1020237035777A KR20237035777A KR20230173108A KR 20230173108 A KR20230173108 A KR 20230173108A KR 1020237035777 A KR1020237035777 A KR 1020237035777A KR 20237035777 A KR20237035777 A KR 20237035777A KR 20230173108 A KR20230173108 A KR 20230173108A
Authority
KR
South Korea
Prior art keywords
cancer
treatment
sephb4
ephb4
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237035777A
Other languages
English (en)
Korean (ko)
Inventor
발레리 크라스노페로브
Original Assignee
발레리 크라스노페로브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 발레리 크라스노페로브 filed Critical 발레리 크라스노페로브
Publication of KR20230173108A publication Critical patent/KR20230173108A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237035777A 2021-03-18 2022-03-18 암 치료에서 1차 요법으로 sEphB4-HSA 융합 단백질의 용도 Pending KR20230173108A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162691P 2021-03-18 2021-03-18
US63/162,691 2021-03-18
PCT/US2022/020878 WO2022198001A1 (en) 2021-03-18 2022-03-18 Use of sephb4-hsa fusion protein as a first-line therapy in cancer treatment

Publications (1)

Publication Number Publication Date
KR20230173108A true KR20230173108A (ko) 2023-12-26

Family

ID=83320877

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237035777A Pending KR20230173108A (ko) 2021-03-18 2022-03-18 암 치료에서 1차 요법으로 sEphB4-HSA 융합 단백질의 용도

Country Status (8)

Country Link
US (1) US20240156908A1 (https=)
EP (1) EP4308149A4 (https=)
JP (1) JP2024511995A (https=)
KR (1) KR20230173108A (https=)
CN (1) CN117120074A (https=)
AU (1) AU2022239581A1 (https=)
CA (1) CA3211742A1 (https=)
WO (1) WO2022198001A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274305B1 (en) * 1996-12-19 2001-08-14 Tufts University Inhibiting proliferation of cancer cells
EP3368551B1 (en) * 2015-10-27 2023-07-12 The University Of Queensland A modified epha4 polypeptide
CA3139416A1 (en) * 2019-02-13 2020-08-20 Vasgene Therapeutics Inc Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer
WO2020190977A1 (en) * 2019-03-17 2020-09-24 Vasgene Therapeutics Inc Treatment of cancers using sephb4-hsa fusion proteins

Also Published As

Publication number Publication date
CN117120074A (zh) 2023-11-24
WO2022198001A1 (en) 2022-09-22
AU2022239581A1 (en) 2023-10-26
CA3211742A1 (en) 2022-09-22
EP4308149A4 (en) 2025-02-26
JP2024511995A (ja) 2024-03-18
US20240156908A1 (en) 2024-05-16
EP4308149A1 (en) 2024-01-24

Similar Documents

Publication Publication Date Title
DK2101807T3 (en) VEGF-SPECIFIC ANTAGONISTS FOR ADMINISTRATIVE AND NEOADVERTIVE TREATMENT AND TREATMENT OF TEMPERATURES IN EARLY STAGE
TWI780994B (zh) 用於治療非小細胞肺癌之抗b7-h1及抗ctla-4抗體
JP2020524694A (ja) がんの処置における使用のためのＩＬ−１β結合性抗体
KR20170015525A (ko) 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
JP7809324B2 (ja) ｓＥｐｈＢ４－ＨＳＡ融合タンパク質を用いたがんの治療
US20240156908A1 (en) USE OF sEphB4-HSA FUSION PROTEIN AS A FIRST-LINE THERAPY IN CANCER TREATMENT
WO2024213745A1 (en) Combination for treatment and prevention of cancer
KR20240053651A (ko) 에프린b2 발현을 이용한 암의 진단 방법
KR20250131777A (ko) 암의 치료 및 예방을 위한 조합물
JP2026514110A (ja) がんの処置および予防のための組合せ
AU2014201795B2 (en) VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
AU2016213830A1 (en) VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
HK1133210B (en) Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231018

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250317

Comment text: Request for Examination of Application